Silence Therapeutics combines explosive revenue growth and an engine-favored asymmetric setup with severe cash burn and volatile earnings, making it a high-risk, high-reward growth story.
Thesis pillars
- Extreme Cash Burn Rule Of 40 Fail→Stable
- Explosive Revenue Growth→Stable
- Overbought Momentum Asymmetric Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 5, 2026
Silence Therapeutics Plc - Amer (SLN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.71: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: Elevated put/call ratio: 2.79; Below-average business quality; Rich valuation.
Silence Therapeutics is a UK-based clinical-stage biopharmaceutical company developing siRNA (RNA interference) therapeutics via its mRNAi GOLD platform, with a pipeline led by divesiran (Phase 2, polycythemia vera) and zerlasiran (Phase 3-ready, cardiovascular disease driven by... Read more
Sell if holding. Engine safety override at $19.71: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: Elevated put/call ratio: 2.79; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.2/10, moderate confidence.
Passes 3/7 gates (positive momentum, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and earnings proximity 6d<=7d. Suitability: speculative.
About Silence Therapeutics Plc - Amer
About Silence Therapeutics Plc - Amer
Silence Therapeutics, a London-based clinical-stage biopharmaceutical company trading via ADSs on Nasdaq, reported an $88.6 million net loss in 2025 against a $562.6 million accumulated deficit, with no products yet approved or generating revenue. Its lead rare-disease candidate, divesiran, is in a fully enrolled Phase 2 trial for polycythemia vera with topline results due in the third quarter of 2026, while zerlasiran, its Lp(a)-targeting cardiovascular candidate, is Phase 3 ready and awaiting a development partner.
As a pre-revenue company, Silence's income depends on collaboration and licensing deals rather than product sales: AstraZeneca funded and ran Phase 1 development of SLN312, an ANGPTL3-targeting candidate, but notified Silence on March 4, 2026 that it will not advance the program beyond Phase 1, returning full development, manufacturing, and commercialization rights to Silence. The company's mRNAi GOLD platform conjugates siRNA to GalNAc for targeted liver-cell delivery, a modality already validated in divesiran's Phase 1 SANRECO results, which eliminated therapeutic phlebotomies across 21 polycythemia vera patients dosed once every six weeks. Beyond the two lead programs, earlier-stage candidates include SLN548 (complement factor B, seeking a partner for clinical development), SLN365 (GPR146, cholesterol), and SLN098 (INHBE, obesity), all still in preclinical or early discovery. Clinical trial material is produced by third-party contract manufacturers rather than in-house facilities, a dependency the 10-K flags as a potential source of trial delay.
Show full overview
Silence's near-term commercial path runs through business development rather than its own trials: zerlasiran is explicitly described as awaiting a third-party partner for Phase 3 funding and future commercialization, and SLN548 likewise needs an outside partner just to begin clinical development, meaning two of the company's most derisked assets cannot advance without a deal Silence does not control the timing of. That dependency was reinforced in March 2026 when AstraZeneca, its only named large-pharma collaborator, opted out of SLN312 beyond Phase 1 — a decision that returns the asset to Silence but also removes an existing example of the partnership model the company is counting on to fund zerlasiran and SLN548.
See also: Healthcare · Biotechnology
From Silence Therapeutics Plc - Amer's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Silence Therapeutics Plc - Amer
Latest news
- NEWS Halper Sadeh LLC Investigates Silence Therapeutics plc Acquisition — fiscal.ai Oct 23, 2026 negative
- NEWS HC Wainwright & Co. Downgrades Silence Therapeutics to Neutral, Lowers Price Target to $20 — benzinga Oct 21, 2026 negative
- NEWS Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone — benzinga Oct 20, 2026 neutral
- NEWS Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Rad — benzinga Oct 19, 2026 neutral
- NEWS Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October — benzinga Oct 19, 2026 neutral
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-05-18Item 1.01LOWEntered into a new Open Market Sale Agreement (ATM) with Jefferies LLC for at-the-market ADS offerings, replacing the October 2021 agreement with Jefferies. Routine capital-raising facility; the company is not obligated to sell any ADSs under it.SEC filing →
- 2026-05-18Item 1.02MEDIUMTerminated the prior October 2021 Open Market Sale Agreement with Jefferies LLC, effective May 18, 2026, concurrent with entering a replacement ATM sales agreement with the same counterparty.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.71: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: Elevated put/call ratio: 2.79; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $18.33. Score 4.2/10, moderate confidence.
Analyst target $16.79 reached (−14.8% from $19.71); no take-profit level is published. Prior stop was $18.33. Stop-loss: $18.33.
Target reached (-14.8% upside); Quality below floor (3.4 < 4.0).
Silence Therapeutics Plc - Amer trades at a P/E of N/A (forward -51.9). TrendMatrix value score: 3.0/10. Verdict: Sell.
What does Silence Therapeutics Plc - Amer do?Silence Therapeutics is a UK-based clinical-stage biopharmaceutical company developing siRNA (RNA interference)...
Silence Therapeutics is a UK-based clinical-stage biopharmaceutical company developing siRNA (RNA interference) therapeutics via its mRNAi GOLD platform, with a pipeline led by divesiran (Phase 2, polycythemia vera) and zerlasiran (Phase 3-ready, cardiovascular disease driven by elevated Lp(a)). The company has never generated product revenue, relying on collaboration agreements such as its partnership with AstraZeneca on SLN312, and reported an $88.6 million net loss and $562.6 million accumulated deficit for 2025.